Mubritinib is primarily investigated for its potential in cancer therapy, particularly in targeting specific pathways involved in tumor growth and survival. It functions as an inhibitor of HER2/neu tyrosine kinase, which is often overexpressed in certain types of cancers, such as breast cancer. By blocking this kinase, Mubritinib aims to disrupt the signaling pathways that promote cancer cell proliferation and survival. Research has focused on its efficacy in preclinical models, exploring its ability to inhibit tumor growth and enhance the effectiveness of other anticancer treatments. While its development has not progressed to widespread clinical use, studies continue to evaluate its potential as a targeted therapy for HER2-positive cancers.